# Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma

> **NCT05590221** · PHASE2 · UNKNOWN · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 20 (estimated)

## Conditions studied

- B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** Relmacabtagene Autoleucel
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT05590221
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-03
- **Primary completion:** 2024-02-10
- **Final completion:** 2024-12-10
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05590221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05590221, "Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05590221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*